(a) BRCA2 deficient HCT116 are more sensitive to CX-5461 than isogenic BRCA2 WT cells. Drug sensitivity to CX-5461 was compared between BRCA2 proficient and deficient cells in HCT116. Data from BRCA2 proficient cell lines (WT and BRCA2 heterozygous) were combined, and data from BRCA2 deficient (B18 and B46) were also combined. 9 independent WST-1 assay results were summarized (each with internal replicates, mean number of internal replicates=3).
The mean IC50 ratio across the 9 experiments was 8.997 (95%CI, . A t-test of the differences between BRCA2 proficient and deficient cell lines across 9 experiments yields t(8)=8.76, p = 0.000023. A simple non-parametric test (Wilcoxon sign test) for the differences in IC50 across the nine experiments yields p = 0.0039. Thus there is strong statistical evidence of a consistent difference in IC50 dose-response values for the BRCA2 deficient and proficient cell lines for the drug CX-5461. (b and c) BRCA2 knockout cells are not more sensitive to actinomycin (b) and cycloheximide (c). The dose sensitivity in HCT116 is displayed by WST-1 assay, and the results of all 3 experiments are summarized in isogenic cell line pairs by the green (BRCA2 deficient) and red (BRCA2 wild type) super-smoother curve fit lines (See statistical methods). Drug treatment time is 6 days. (d) BRCA2 knockout DLD1 cells are highly sensitive to CX-5461 shown by clonogenic assay. Drug treatment time is 12 days. Experiments were repeated twice and similar results were obtained. mean IC50 difference across the 4 experiments was 12.2 (95%CI, 6.03-25.1). A t-test of the 4 experiments, testing the hypothesis of no difference in IC50 values for BRCA2 proficient and deficient DLD1 cells yields t(3)=11.14, p =0.0015. Thus we reject the null hypothesis and conclude that there is sufficient statistical evidence to suggest a difference in IC50 values for the BRCA2 proficient and deficient genotypes of the DLD1 cell line. (b) BRCA2 deficient PEO1 ovarian cancer cells are more sensitive to CX-5461 than C4-2 revertant BRCA2 WT control cells. Three WST-1 assay results exhibited the higher sensitivity of BRCA2 -/-(PEO1) cells to CX-5461 relative to BRCA2 proficient cells (C4-2). The mean IC50 difference across the 3 experiments was 8. 46 (95%CI, ) on the raw dose scale. A t-test of the 3 experiments, testing the hypothesis of no difference in IC50 values for BRCA2 proficient and deficient PEO1-derived cells yields t(2)=30.8, p = 0.0011. Thus we reject the null hypothesis and conclude that there is sufficient statistical evidence to suggest a difference in IC50 values for the BRCA2 proficient (C4-2) and deficient (PEO1) genotypes of the PEO1 cell line. (c) BRCA2 knockout mouse breast tumor cells were highly sensitive to CX-5461 as demonstrated by WST-1 assay. The results of all 3 experiments are summarized in isogenic cell line pairs by the green (BRCA2 deficient) and red (BRCA2 wild type) super-smoother curve fit lines (See statistical methods). (d) BRCA2 deficient (knocking down by siRNA) U2OS cells are more sensitive to CX-5461 than non-targeting control cells. BRCA2 was knocked down 3 times with siRNA in U2OS cells and drug sensitivity to CX-5461 was compared between cells with BRCA2 knocked down and non-targeting control. The mean IC50 difference across the 3 experiments was 2.89 (95%CI, 1.024-8.152) on the raw dose scale. A t-test of the 3 experiments, testing the hypothesis of no difference in IC50 values for BRCA2 proficient and deficient U2OS cells yields t(2)=4.40, p = 0.048. Thus we reject the null hypothesis and conclude that there is sufficient statistical evidence to suggest a difference in IC50 values for the BRCA2 proficient (siNTS) and deficient (siBRCA2) Figure. 3 . The selective toxicity of CX-5461 to BRCA2 deficiency is not due to rDNA transcription inhibition. (a) Drug sensitivity to BMH-21 was compared between BRCA2 proficient and deficient cells in HCT116. 4 independent WST-1 experiments were performed. The mean IC50 difference across the 4 experiments was 1.12 (95%CI, 0.474-2.647) on the raw dose scale. A t-test of the 4 differences, testing the hypothesis of no difference in IC50 values for BRCA2 proficient and deficient HCT116 cells yields t(3)=0.42, p = 0.71. Thus we fail to reject the null hypothesis and conclude that there is insufficient statistical evidence to suggest a difference in IC50 values for the BRCA2 proficient (WT, BRCA2 +/-) and deficient (B18, B46) genotypes of the HCT116 cell line. (b) Drug sensitivity to BMH-21 was compared between BRCA2 proficient and deficient cells in DLD1. 3 independent WST-1 experiments were performed. The mean IC50 difference across the 3 experiments was 0.688 (raw dose scale ratio, 95%CI, 0.0578-8.18). A t-test of the 3 differences, testing the hypothesis of no difference in IC50 values for BRCA2 proficient and deficient DLD1 cells yields t(2)=-0.65, p = 0.58. Thus we fail to reject the null hypothesis and conclude that there is insufficient statistical evidence to suggest a difference in IC50 values for the BRCA2 proficient (WT, BRAC2 +/-) and deficient (BRCA2 -/-) genotypes of the DLD1 cell line. (c) polR1B was effectively knocked down by siRNA, and knocking down polR1B decreased the expression of 45s pre-rRNA in U2OS. The expression of 45s pre-rRNA was analyzed by Taqman assay*** and Sybrgreen assay. Mean fold change in gene expression and 95%Cis are shown. (d) BRCA2 knockout cells are highly sensitive to CX-3543 in DLD1. A graphical portrayal of the assay results across four independent experiments is shown with a smoother line for each cell genotype overlaid. There is strong statistical evidence of a difference in cell proliferation rates between the BRCA2 proficient (WT) and BRCA2 homozygous genotypes (BHOM) (F-test p<10-15) in the presence of CX-3543. Drug sensitivity of BRCA2 heterozygous cells (BHET) is not different from WT cells (p>0.2 by F-test across all drug concentrations tested). (e and f) Cell viability was measured after polR1B and BRCA2 knockdown in HCT116 (e) and U2OS (f) by WST-1 assay. WST-1 intensity normalized to control was shown with mean value and 95%CI. Double knockdown for polR1B and BRCA2 differs significantly from any single knockdown in HCT116 (p<0.0001, omnibus test), but not in U2OS.
(g) 45S pre-rRNA level measured by RT-PCR after CX-5461, CX-3543 and BMH-21 treatment in WT and BRCA2 -/-HCT116 cells. Drug incubation time was 2 hours. Fold change estimates and unadjusted 95% CIs of 45s pre-rRNA levels under drug treatment condition versus vehicle control are shown. qPCR was conducted using both Taqman and SYBR Green assays. Beta-actin was a loading control, and actinomycin treatment was a control for the reduction of 45s pre-rRNA. (a) The level of γ-H2AX increased upon CX-5461 and CX-3543 treatment for 24 hours in HCT116 via western blot analysis. The increased γ-H2AX level is not the result of cell death as indicated by the absence of PARP1 degradation. HU (5mM 2hr), IR (10Gy 1hr), and CPT (0.5 µM 24hr) were used as controls for the induction of DNA damage or apoptosis. -7 M CX-5461 treatment. RAD51 foci analysis was from at least three experiments upon 24hr of CX-5461 treatment. Bars represent 95% confidence interval. P-values were obtained from one-tail randomization tests. ***p<0.001. (h) Yeast lacking RAD52 showed increased growth sensitivity to the CX-5461. Growth curves of isogenic wild type (WT) and rad52∆strains with the CX-5461 at the indicated concentrations for 24hrs at 30°C. Each experiment was triplicated and averaged, and the area under each curve was measured (right panels) (mean ± SEM; n=3) (*** p<0.0001 t-test). Table 2 . List of C. elegans mutants tested for sensitivity to 100 µM CX-5461 using a chronic exposure assay. + indicates that the mutant was sensitive to CX-5461 compared to carrier alone in 3/3 assays. The patient derived xenograft (PDX) tumor was derived from a 53 year old Caucasian woman with Stage IV TNBC. Prior to the PDX tumor harvesting, the patient was treated with Cyclophosphamide/ Doxorubicin/Paclitaxel for duration of 28 months. Upon treatment failure, she was put on Docetaxel/ Capecitabine for 10 months. The patient was then placed on treatments with Capecitabine, Eribulin and Doxil (each as a single agent) with progression of her cancer soon after. Next Generation Sequencing (NGS) revealed BRCA1 mutation (non-deleterious).
Supplementary

CTG-0012
The PDX tumor was derived from a 36 year old Caucasian woman with Stage IV TNBC. Prior to the PDX tumor harvesting, she was treated with Docetaxel for a duration of 12 months before her disease progressed. The patient was subsequently treated with Capecitabine/Bevacizumab and Vinorelbine/ Bevacizumab but failed both treatments. NGS Data revealed a deleterious somatic mutation in BRCA1 as well as a germline mutation in BRCA2.
CTG-0888
sBRCA2m (X3030X-frameshift) gBRCA1m (K1183R; S1634G; P871L; E1038G)
The PDX tumor was derived from a 43 year old Caucasian woman with Stage III TNBC. Prior to PDX tumor harvesting, she was treated with Cyclophosphamide/Doxorubicin/Paclitaxel for a duration of 9 months. NGS data revealed a deleterious somatic mutation in BRCA2 and germline mutations in BRCA1
TNBC patient with germline BRCA1 exon 11 missense variant c2477C>A; was diagnosed at 39; with family history of ovary cancer at age 37; heavily pretreated in phase I clinic (including prior platinum).
CFIB-70620 gBRCA2m (c793+6T>C)
35 year TNBC patient with BRCA2 variant; germline BRCA2 -EXON09 c793+6T>C; from somewhere in Asia; multiple family members with "breast lumps"; somatic TP53 mutation; sample is from postneoadjuvant FEC/D.; subsequently had minor response to gemcitabine/cisplatin; very aggressive disease died within 1 year of breast surgery.
Supplementary Table 4. Summary of breast cancer cell lines used in Figure 7d
Cell Line Name BMH21 
